Investigating novel treatments for a brighter tomorrow

Anxiety Outpatient – MindMed-300

This study is designed to evaluate the efficacy of a single dose of 100 µg of MM-120 (D-lysergic acid diethylamide D-tartrate), versus placebo, for the treatment of anxiety symptoms.
This study is sponsored by Mind Medicine, Inc.

Depression Outpatient – MindMed-310

This study is designed to evaluate the efficacy of a single dose of 100 µg of MM-120 (D-lysergic acid diethylamide D-tartrate), versus placebo, for the treatment of depression symptoms.
This study is sponsored by Mind Medicine, Inc.

Depression Outpatient – Compass-006

Do you continue to experience depressive episodes, despite having tried more than one anti-depressant medication?

This study is designed to investigate the efficacy of COMP360 (25 mg compared to 1mg), administered with psychological support in improving symptoms of depression.

This study is sponsored by Compass Pathways.

Depression Outpatient – Cybin 003-002

For adults with a diagnosis of Major Depressive Disorder (MDD) currently experiencing a Major Depressive Episode (MDE).

The goal of this study is to evaluate the efficacy, safety, and tolerability of CYB003 15 mg, compared to placebo, in treating symptoms of MDD in adult participants.

This study is sponsored by Cybin.

Obesity Outpatient – Viking 2745-301

For adults living with obesity, or adults who are overweight with at least one comorbidity.

The goal of this study is to demonstrate that VK2735 12.5 mg and/or 17.5 mg QW is superior to placebo for % change in body weight.

This study is sponsored by Viking Therapeutics.

OCD Outpatient – Biohaven-302

Do you have OCD and are struggling to find effective treatment?

This study is evaluating the efficacy of a new medication as adjunctive therapy compared to placebo in subjects with OCD who have had an inadequate response to their current OCD treatment. Study sponsored by Biohaven Pharmaceuticals in collaboration with NOC

Schizophrenia Inpatient – Maplight-007C-MA

For adults with schizophrenia who warrant inpatient hospitalization.

The goal of this study is to assess the efficacy, safety, and tolerability of ML-007C-MA compared with placebo in reducing symptoms of schizophrenia in adults experiencing an acute exacerbation of psychosis.

This study is sponsored by Maplight Therapeutics.

Schizophrenia Inpatient – Neurocrine-3029

For adults with schizophrenia who warrant inpatient hospitalization.

The goal of this study is to assess the efficacy, safety, and tolerability of NBI-1117568 in adults with schizophrenia.

This study is sponsored by Neurocrine Biosciences, Inc.

Schizophrenia Inpatient – Otsuka-00035

Treatment for worsening of symptoms in patients with schizophrenia.

The primary objective of this study is to evaluate the efficacy, safety, and tolerability of SEP-363856 (75 mg to 100 mg /daily) compared to a placebo in adults experiencing an acute exacerbation of schizophrenia.

This study is sponsored by Otsuka Pharmaceutical.